The BioPharm Brief: Innovation, Gene Therapy Momentum, and Next-Gen ADCs Lead Today’s Headlines
The latest Ron Lanton Report shows biopharma innovation moving beyond Boston and San Francisco into emerging regions powered by academic collaborations, venture capital, and niche talent pools. The European Medicines Agency issued a positive opinion on Novartis’ intrathecal onasemnogene abeparvovec, expanding gene‑therapy options for older SMA patients. Alphamab Oncology will unveil Phase 1 data on its bispecific ADC JSKN016, which targets TROP2 and HER3 in heavily pretreated HER2‑negative breast cancer. These developments highlight a broader shift toward distributed R&D, novel delivery routes, and multi‑targeted oncology platforms.
How Advances in Chronic Lymphocytic Leukemia Medications Are Shaping Patient Care Protocols
Over the past decade, chronic lymphocytic leukemia (CLL) treatment has shifted from broad chemotherapy to targeted, oral therapies such as BTK and BCL‑2 inhibitors, monoclonal antibodies, and personalized regimens based on genetic profiling. These drugs deliver higher response rates, longer...
Nanodrum Beats Identify Bacterial Infections by Sound
Researchers report that bacterial infections could be diagnosed with sound, using a nanoscale drum kit. Different bacteria play different rhythms on the drum. https://spectrum.ieee.org/soundcell-nanodrums-identify-bacteria-sound
The Slow March of Clinical Biomarkers to Become Surrogate Endpoints
Clinicians are urging the FDA to recognize more clinical biomarkers as surrogate endpoints, hoping to accelerate drug approvals and reduce trial durations. Regulators remain cautious, approving only six biomarkers through the 2007 Biomarker Qualification Programme and often demanding definitive clinical...
No-Option CLTI Patients Report Better QoL After Blood Flow Diversion Therapy: PROMISE III
The PROMISE III trial shows that transcatheter arterialization of the deep veins (TADV) using the LimFlow device markedly improves quality of life for no‑option chronic limb‑threatening ischemia (CLTI) patients. At six months, 80% of participants had healed or healing foot wounds...
Alphamab Oncology to Present Phase 1 Data on Bispecific ADC JSKN016 in HER2-Negative Breast Cancer at ASCO 2026
Alphamab Oncology will unveil Phase 1 results for its bispecific antibody‑drug conjugate JSKN016 at ASCO 2026, focusing on HER2‑negative breast cancer. The first‑in‑human trial in China demonstrated antitumor activity and a manageable safety profile in heavily pretreated patients, including triple‑negative cases. JSKN016...
One Biosciences Chooses Albany, NY, as Its U.S. Location
Paris‑based One Biosciences, backed by Institut Curie, announced its first U.S. hub in Albany, New York, where it will build a high‑complexity laboratory and computational analytics operation. The state’s Empire State Development agency will provide up to $525,000 in performance‑based...
Sunnybrook Announces $41-Million Gift to Advance Canada’s Global Leadership in Clinical Trials
Sunnybrook Health Sciences Centre announced a $41 million CAD (≈$30 million USD) philanthropic gift to expand its Sunnybrook Clinical Trials program. The funding creates new leadership positions, boosts biobanking, data management and precision diagnostics, and supports first‑time investigators. By strengthening infrastructure and...
Scaling Cheap In‑Vivo Causal Testing for Age‑Related Diseases
AI has made hypothesis generation in bio cheap. Anyone can get an answer to ‘could this play a role in my disease’, but how do we go from ‘could’ to ‘does’? The scarce resource now is causal evidence to test hypotheses...
Semaglutide NAION Risk Higher than Risk with SGLT2 Inhibitors
A VA‑based study published in JAMA Ophthalmology found that patients with type 2 diabetes taking semaglutide experienced more than double the risk of nonarteritic anterior ischemic optic neuropathy (NAION) compared with those on SGLT2 inhibitors. The analysis covered 102,361 veterans, with...
Policy Watch: FDA Moves to Implement Trump Order on Psychedelic Drugs
President Trump’s recent executive order tasked the FDA and ARPA‑H with accelerating psychedelic research. In response, the FDA issued Commissioner’s National Priority Vouchers to three firms—Compass Pathways, Transcend Therapeutics and the Usona Institute—fast‑tracking review of psilocybin and methylone candidates for...
STAT+: FDA to Speed up Review of Three Psychedelics as Mental Health Treatments
The FDA announced it will grant priority‑review vouchers to accelerate the evaluation of three psychedelic therapies—Compass Pathways’ psilocybin for treatment‑resistant depression, Usona Institute’s psilocybin for major depressive disorder, and Transcend Therapeutics’ MDMA‑like compound for PTSD. The move is part of...
Carefully Guided FGF8 Expression via Gene Therapy Enhances Digit Tip Regrowth in Mice
Researchers used a zebrafish-derived tissue‑regeneration enhancer to deliver fibroblast growth factor 8 (FGF8) via adeno‑associated virus, achieving focused up‑regulation of the gene in mouse digit tips. The therapy partially rescued regeneration in mice lacking SP6/SP8 transcription factors and accelerated tip...
Canadian Life Sciences Is at a “Generational Moment,” But Experts Disagree on Its Future
Canadian life sciences, contributing roughly 2% of GDP, is at a pivotal juncture as federal and provincial governments roll out new support mechanisms. BIOTECanada highlighted a federal task force, a Life Sciences Fund and BDC Capital’s $150 million CAD (~$110 million USD)...
Genomic Tool Untangles How Microbes Spread—Even when They Look Almost Identical
Researchers unveiled TRACS, a new genomic algorithm that pinpoints how microbes spread by detecting minute genetic differences. Published in Nature Microbiology, the tool successfully mapped transmission of SARS‑CoV‑2, Streptococcus pneumoniae, and Plasmodium falciparum across diverse cohorts. By distinguishing recent direct...
Protecting Innovation for Psychedelic Therapies Fast-Tracked Under New Executive Order
President Donald J. Trump signed an executive order that fast‑tracks FDA approval for breakthrough psychedelic therapies targeting serious mental illness. The order creates a Commissioner’s National Priority Voucher program, establishes pre‑approval patient access pathways, and earmarks $50 million in federal funding...
EU Biotech Act: The European Commission’s Landmark Proposal to Strengthen Biotechnology in Europe
On December 2025 the European Commission unveiled the European Biotech Act, a sweeping proposal aimed at cementing the EU’s position as a global biotech leader against the United States and China. The Act introduces fast‑track regulatory pathways, a strategic‑project framework...
Re: England Athletics Promotion of Medical Knee Procedure to Runners on Eve of London Marathon Is Condemned by Experts
England Athletics recently promoted Arthrosamid, a Class IIb implantable knee device, to runners ahead of the London Marathon. The product, marketed as a "drug," bypasses many safety tests because it carries a CE mark that allows manufacturer self‑certification. A UK...
FDA Awards Three Priority Review Vouchers For Psychedelics
On April 24, 2026 the FDA announced it will issue three priority review vouchers to companies developing psychedelic therapies. The vouchers cover two psilocybin programs targeting treatment‑resistant and major depressive disorder, and a methylone program for post‑traumatic stress disorder. The...
FDA Unveils Three Psychedelic-Focused Commissioner Vouchers
The U.S. Food and Drug Administration announced it has issued fast‑track “commissioner vouchers” to three psychedelic‑focused companies. The agency withheld the identities of the sponsors, a move that surprised investors and analysts. The vouchers are designed to expedite regulatory review,...
Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie
The U.S. Food and Drug Administration issued a complete response letter to AbbVie, rejecting its biologics license application for trenibotulinumtoxinE due to manufacturing and CMC deficiencies. The setback delays AbbVie’s entry into the lucrative neurotoxin market, a segment dominated by...
AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials
Isomorphic Labs, the DeepMind spinoff behind AlphaFold, announced that its AI‑designed drug candidates will soon enter human clinical trials. The company’s new IsoDDE engine claims to double the accuracy of AlphaFold 3 in predicting protein‑small‑molecule interactions. Partnerships with Eli Lilly and Novartis...
Learning, Predicting, and Interpreting Omics Data with Biologically Informed Models
Pablo Rodriguez‑Mier presented CORNETO, a unified optimization framework that fuses prior biological knowledge with high‑throughput omics data to infer context‑specific networks. The method was applied in the EU‑funded DECIDER project to pinpoint molecular mechanisms driving chemotherapy resistance in high‑grade serous...
Designer Baby Companies Are in Turmoil
Two high‑profile germline‑editing startups—Bootstrap Bio and Manhattan Genomics—have ceased operations within a year of launching. Bootstrap Bio folded after running out of capital and was further tarnished by the federal arrest of its chief science officer on child‑sex‑trafficking charges. Manhattan...
The Humility Of Bioscientists
Gene‑editing tools like CRISPR‑Cas9 are moving from rare‑disease therapies to agriculture and livestock, promising scalable health and climate benefits. Researchers such as Nobel laureate Jennifer Doudna and genome pioneer Craig Venter stress that the technology’s power outpaces our understanding of...
Building a Better Delivery System for Gene Editing Machines by Re-Engineering the Cellular Factory
A genome‑wide knockout screen conducted by the Whitehead Institute revealed specific producer‑cell genes that govern the assembly and potency of virus‑like particles (VLPs) used for gene‑editing delivery. Disabling a single brake gene dramatically increased guide‑RNA loading, boosting particle potency across...
Vertical AI Beats Generic Models in Enzyme Engineering
Foundation models are powerful. They're also generic. And in industrial enzyme engineering, generic doesn't cut it. #SynBioBeta2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: https://t.co/8abYWJ1GbK The industrial last mile of...
Human Genetic Optimization Funding Claim Is Pure Fantasy
From Mother Jones story on polygenic selection and embryo editing plans. Absolutely zero chance that human genetic optimization companies raised $36.5 billion in 2024. This number is fantasy. https://t.co/we6euyIMXv
Longevity Revolution Challenges 65‑Year Life Expectancy Model
A wave of anti‑aging breakthroughs is prompting scholars and innovators to call the traditional 65‑year life expectancy model obsolete. With tens of millions now likely to reach their 80s and 90s, the article examines the mismatch between longer healthspans and...
Readout LOUD Interview Explores Kelonia and Eli Lilly
Our Readout LOUD interview with @BRobertsVC about Kelonia and $LLY in print form. https://t.co/DsfGxwcvS3 via @statnews
ER-100 Cleared for Trials; Safety Promising, Translation Uncertain
So far, the data suggest ER-100 should be safe in humans, and the FDA has cleared us to move into clinical trials. Translation from primates to humans is never guaranteed If it doesn’t work as hoped, we’ll learn & improve, just...
Cornell Study Shows Stem‑Cell Vesicles Can Halt Cellular Aging in Lab
Scientists at Cornell University's College of Veterinary Medicine demonstrated that extracellular vesicles derived from embryonic stem cells can completely halt cellular senescence in cultured cells. The breakthrough, published in the Journal of Biological Chemistry, could pave the way for next‑generation...
Postmarketing Requirements and Commitments: Reports
The FDA publishes annual reports in the Federal Register detailing the status of post‑marketing requirements (PMRs) and commitments (PMCs) for drugs and biologics, covering both CDER and CBER. These reports summarize data from internal databases and are updated quarterly on...
Trump's Executive Order Fast‑Tracks Psychedelic Therapy Review, Boosting Compass Pathways
President Donald Trump signed an executive order this weekend to shorten clinical‑trial and regulatory timelines for psychedelic medicines. The move shines a spotlight on Compass Pathways, whose late‑stage psilocybin candidate COMP360 is poised for an FDA filing and has $149.6 million...
Glutamine Transport Boost Enhances CAR‑Macrophage Cancer Therapy in Mice
A Sun Yat‑sen University team engineered CAR‑macrophages to overexpress the glutamine transporter SLC38A2, dramatically improving phagocytosis and cytokine release against HER2‑positive breast cancer cells. In mouse models, the modified cells suppressed tumor growth far more than standard CAR‑macrophages, highlighting metabolic...
Creative Biolabs Unveils LNP Conjugation Platform to Accelerate Precision Gene Therapy
Creative Biolabs announced the commercial release of an enhanced lipid‑nanoparticle (LNP) conjugation platform that improves payload stability and tissue targeting for gene‑editing and RNA therapeutics. The platform integrates microfluidic manufacturing and programmable ligand attachment, promising faster preclinical timelines for biotech...
AAN 2026: Tavapadon Post-Hoc Analysis Strengthens Its D1/D5 Agonist Pitch
At the 2026 American Academy of Neurology meeting, AbbVie unveiled post‑hoc results from its Phase III TEMPO‑1 and TEMPO‑2 trials of tavapadon, a once‑daily oral D1/D5 partial agonist for early Parkinson’s disease. The analysis showed statistically significant improvements in seven of...
Reprogrammed Cardiomyocytes Soften the Blow in Heart Attack
A recent study published in the Journal of Molecular and Cellular Cardiology demonstrates that partial reprogramming of mouse cardiomyocytes with three Yamanaka factors (OCT4, SOX2, KLF4 – OSK) enables the cells to complete cytokinesis after a heart attack. By dismantling...
GPT-5 Autonomously Outperforms SOTA Protein Synthesis by 40%
More on our work with @OpenAI where GPT-5 ran our autonomous lab at @Ginkgo and beat state of the art by 40% in cell free protein synthesis 👇
FDA Clears Single‑Trial Path for Cambium Bio’s Elate Ocular Gene Therapy
The U.S. Food and Drug Administration granted Cambium Bio a single‑trial approval route for its Elate Ocular gene therapy, allowing the CAMOMILE‑3 Phase 3 study to serve as the sole pivotal trial. The decision reduces clinical risk, accelerates market entry and...
AI in Oncology Takes Off, Tackling HIV and Liver Disease, Pharma’s Recent Gains
At AACR 2026 in San Diego, AI-powered platforms took center stage, signaling a rapid shift toward data‑driven oncology. Parallel research revealed CRISPR screens that mapped CD4+ T‑cell genes that either promote or block HIV infection, while synthetic‑biology engineers demonstrated implantable...
Lilly Slides as FDA Plans Psychedelic Voucher Program
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics https://t.co/kWvYtFeif0 $LLY - 4% $NVO + 6% $REGN $AMGN $BBOT #biotech
AAN 2026: Head-to-Head Trial Shows Superiority of Qulipta for Migraine Prevention
AbbVie presented Phase IIIb TEMPLE trial data at AAN 2026, showing its oral gepant Qulipta outperforms topiramate in migraine prevention. Over 24 weeks, Qulipta had a 12.1% discontinuation rate versus 29.6% for topiramate and achieved a 73.7% responder rate (>50% reduction in...
Sanofi MS Drug Rejected in US Gets an Endorsement in Europe
Sanofi’s experimental multiple‑sclerosis drug tolebrutinib, marketed as Cenrifki, received a positive recommendation from the European Medicines Agency for secondary progressive MS, after the U.S. FDA rejected it earlier this year. The EMA’s endorsement paves the way for a final approval...
New Psychedelic Trials Target Depression and PTSD
Compass Pathways’ psilocybin (COMP360) for treatment-resistant depression (TRD) Usona Institute’s psilocybin for major depressive disorder (MDD) Otsuka’s methylone (TSND-201) for PTSD
Drug Digest: Examining the Architecture of Next-Gen Biotherapeutic Modalities
Minaris Advanced Therapies’ chief commercial and technology officer, Dr. Eytan Abraham, discussed how multifunctional biotherapeutics are merging antibodies, ADCs and engineered cells to create more precise, personalized treatments. He highlighted multi‑targeting cell designs that improve specificity and reduce disease escape,...
Biogen Seeks Darzalex Rivalry in China for Multiple Myeloma with Felzartamab Deal
Biogen has secured exclusive rights to TJ Biopharma’s anti‑CD38 antibody felzartamab in Greater China for up to $850 million, including control of a pending biologics licence application for relapsed and refractory multiple myeloma. The drug will be manufactured domestically at TJ...
Lantern Pharma to Debut Public Demonstration of withZeta.ai – A Platform to Conquer Rare Cancers on April 30 Following AACR...
Lantern Pharma announced a public, unscripted demonstration of its withZeta.ai AI co‑scientist platform on April 30, 2026. CEO Panna Sharma will lead two live sessions—morning and afternoon ET—to showcase real‑time drug‑discovery workflows for rare cancers. The event follows the platform’s...
Novartis Pulls Pluvicto Prostate Cancer Label Expansion Filing in the EU
Novartis has pulled its European Medicines Agency (EMA) application to extend the label of Pluvicto, its lutetium‑177 PSMA‑targeted radioligand therapy, into earlier‑stage prostate cancer. The drug already received approval for this indication in the United States and the United Kingdom,...
GPX4 Inhibitors Eradicate Senescent Tumor Cells, Boost Chemo Efficacy
GPX4 inhibitors discovered that kill "zombie" senescent cells from tumors (increased w/ chemoRx) and effective in multiple preclinical models vs cancer, a new potential strategy to pursue in clinical trials https://t.co/lYX7xkI9xF @NatureCellBio https://t.co/mxbjzRQPck